Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Hong Kong · Delayed Price · Currency is HKD 19.33
+0.86 (4.66%)
Mar 6, 2026, 4:08 PM HKT
HKG:1877 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,498 | 1,876 | 1,474 | 1,453 | 3,768 |
Other Revenue | - | 72.73 | 28.4 | - | 257.09 |
| 2,498 | 1,948 | 1,503 | 1,453 | 4,025 | |
Revenue Growth (YoY) | 28.23% | 29.67% | 3.38% | -63.89% | 152.36% |
Cost of Revenue | - | 523.54 | 634.39 | 526.28 | 1,258 |
Gross Profit | 2,498 | 1,425 | 868.16 | 927.21 | 2,767 |
Selling, General & Admin | - | 1,508 | 1,381 | 1,294 | 1,377 |
Research & Development | - | 1,275 | 1,937 | 2,384 | 2,069 |
Other Operating Expenses | 3,496 | 10.35 | 7.54 | 11.75 | 7.07 |
Operating Expenses | 3,496 | 2,779 | 3,344 | 3,690 | 3,453 |
Operating Income | -997.89 | -1,354 | -2,476 | -2,763 | -686.06 |
Interest Expense | - | -51.35 | -29.01 | -29.37 | -21.83 |
Interest & Investment Income | - | 43.63 | 173.42 | 61.02 | 30.98 |
Earnings From Equity Investments | - | - | - | -71.03 | - |
Currency Exchange Gain (Loss) | - | 8.27 | -2.66 | -50.05 | -39.94 |
Other Non Operating Income (Expenses) | -23.81 | 29.33 | -38.71 | 117.42 | 0.13 |
EBT Excluding Unusual Items | -1,022 | -1,324 | -2,373 | -2,735 | -716.72 |
Gain (Loss) on Sale of Investments | - | -71.23 | -149.18 | - | 65.75 |
Gain (Loss) on Sale of Assets | - | 11.84 | 28.89 | 27.01 | 0.78 |
Other Unusual Items | - | 25.89 | 1.55 | 32.74 | 55.2 |
Pretax Income | -1,022 | -1,358 | -2,492 | -2,675 | -595 |
Income Tax Expense | -147.32 | 22.55 | 43.99 | -93.11 | 135.53 |
Earnings From Continuing Operations | -874.39 | -1,380 | -2,536 | -2,582 | -730.53 |
Net Income to Company | -874.39 | -1,380 | -2,536 | -2,582 | -730.53 |
Minority Interest in Earnings | - | 99.18 | 252.26 | 196.03 | 9.62 |
Net Income | -874.39 | -1,281 | -2,283 | -2,386 | -720.91 |
Net Income to Common | -874.39 | -1,281 | -2,283 | -2,386 | -720.91 |
Shares Outstanding (Basic) | 1,005 | 985 | 984 | 917 | 890 |
Shares Outstanding (Diluted) | 1,005 | 985 | 984 | 917 | 890 |
Shares Change (YoY) | 2.00% | 0.11% | 7.28% | 3.08% | 8.28% |
EPS (Basic) | -0.87 | -1.30 | -2.32 | -2.60 | -0.81 |
EPS (Diluted) | -0.87 | -1.30 | -2.32 | -2.60 | -0.81 |
Free Cash Flow | - | -2,125 | -2,838 | -2,158 | -1,507 |
Free Cash Flow Per Share | - | -2.16 | -2.88 | -2.35 | -1.69 |
Gross Margin | 100.00% | 73.13% | 57.78% | 63.79% | 68.74% |
Operating Margin | -39.94% | -69.49% | -164.79% | -190.09% | -17.05% |
Profit Margin | -35.00% | -65.75% | -151.97% | -164.16% | -17.91% |
Free Cash Flow Margin | - | -109.06% | -188.85% | -148.50% | -37.44% |
EBITDA | -738.24 | -1,094 | -2,204 | -2,520 | -476.32 |
EBITDA Margin | -29.55% | -56.16% | -146.66% | -173.40% | -11.83% |
D&A For EBITDA | 259.65 | 259.65 | 272.32 | 242.54 | 209.74 |
EBIT | -997.89 | -1,354 | -2,476 | -2,763 | -686.06 |
EBIT Margin | -39.94% | -69.49% | -164.79% | -190.09% | -17.04% |
Revenue as Reported | - | 1,948 | 1,503 | - | 4,025 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.